Which peptides are in the HHS compounding policy of October 30, 2026?
Short answer
Six peptides are listed in Appendix A of HHS’s October 30, 2026 draft enforcement-discretion policy: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.1 No other substance profiled here is in it.1
Each entry below quotes its profile and links to the full answer there.
In the policy 6
Not an FDA-approved drug2
Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,2,3
Is BPC-157 FDA-approved? · BPC-157 vs TB-500 · BPC-157 vs KPV
Not an FDA-approved drug4
Not FDA-approved. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, epitalon acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,4
Not an FDA-approved drug5
Not FDA-approved. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, KPV acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,5
Not an FDA-approved drug6
Not FDA-approved. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, MOTS-c acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,6
Not an FDA-approved drug7
Not FDA-approved. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, Semax free base is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,7
Not an FDA-approved drug8
Not FDA-approved. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, TB-500 acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,8
Is TB-500 FDA-approved? · BPC-157 vs TB-500 · TB-500 vs Thymosin beta-4
Reviewed by FDA for compounding, but not in the policy 15
Not FDA-approved; FDA advised against adding it to the compounding list9,10,11
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. AOD-9604 is not among them.1,3
Is AOD-9604 FDA-approved? · AOD-9604 vs Semaglutide · AOD-9604 vs Tesamorelin
Unapproved new drug in cited enforcement record12
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not among them.1,3
Is CJC-1295 FDA-approved? · CJC-1295 vs Ipamorelin · CJC-1295 vs Sermorelin
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)11
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not among them.1,3
Is GHRP-2 FDA-approved? · GHRP-2 vs GHRP-6 · GHRP-2 vs Ipamorelin
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)11
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-6 is not among them.1,3
Is GHRP-6 FDA-approved? · GHRP-2 vs GHRP-6 · GHRP-6 vs Ipamorelin
Unapproved new drug in cited enforcement record12
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.1,3
Is ipamorelin FDA-approved? · CJC-1295 vs Ipamorelin · Ipamorelin vs Sermorelin
No FDA approval reported; on FDA’s compounding safety-risk list11
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Melanotan II is not among them.1,3
Is Melanotan II FDA-approved? · Melanotan II vs Bremelanotide · Melanotan II vs Afamelanotide
MK-677
Not a peptide: a small molecule often looked up alongside peptides
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)11,16
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. MK-677 is not among them.1,3
Is MK-677 FDA-approved? · MK-677 vs Ipamorelin · MK-677 vs Sermorelin
Not FDA-approved; FDA advised against adding it to the compounding list10,11,18
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin alpha-1 is not among them.1,3
Is thymosin alpha-1 FDA-approved? · Thymosin alpha-1 vs Thymosin beta-4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 2FDA briefing document for BPC-157-related bulk drug substances ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4FDA briefing document for epitalon ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 5FDA briefing document for KPV ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 6FDA briefing document for MOTS-c ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 7FDA briefing document for Semax ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 8FDA briefing document for TB-500 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 9FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 10December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 11Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 12Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 13FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 14503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked July 22, 2026
- 15FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 16October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 17Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 18FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026